Funapide

Funapide
Clinical data
Routes of; administration	By mouth, topical
ATC code	None;
Identifiers
	IUPAC name (7S)-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[6H-furo[2,3-f][1,3]benzodioxole-7,3'-indole]-2'-one;
CAS Number	1259933-16-8 ;
PubChem CID	49836093;
ChemSpider	34500834;
UNII	A5595LHJ2L;
KEGG	D11156;
Chemical and physical data
Formula	C22H14F3NO5
Molar mass	429.351 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C2(C3=CC=CC=C3N(C2=O)CC4=CC=C(O4)C(F)(F)F)C5=CC6=C(C=C5O1)OCO6;
	InChI InChI=1S/C22H14F3NO5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8H,9-11H2/t21-/m0/s1; Key:NEBUOXBYNAHKFV-NRFANRHFSA-N;

Funapide (INN; former developmental codes TV-45070 and XEN402) is a novel analgesic under development by Xenon Pharmaceuticals (formerly in partnership with Teva Pharmaceutical Industries) for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain.^[1]^[2]^[3]^[4] It acts as a small-molecule Na_v1.7 and Na_v1.8 voltage-gated sodium channel blocker.^[1]^[2]^[4] Funapide was evaluated in humans in both oral and topical formulations, and as of July 2014, had reached phase IIb clinical trials.^[1]^[3] Development of the drug was discontinued in 2022.^[5]

Quick Facts Clinical data, Routes ofadministration ...

See also